Clinical Trial

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Protocol Amendment History 5 changes
notable Trial sites expanded: 136 -> 140 locations 2026-07-17
notable Trial sites expanded: 129 -> 133 locations 2026-06-05
notable Trial sites expanded: 122 -> 125 locations 2026-04-25
notable Trial sites expanded: 117 -> 120 locations 2026-04-10
notable Trial sites expanded: 94 -> 116 locations 2026-03-31
Trial Details
NCT Number NCT07213674
Lead Sponsor Amgen
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 750 participants
Start Date 2025-11-28
Primary Completion 2030-01-07 (estimated)
Study Completion 2032-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-16